Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults
about
sameAs
Advances and challenges in malaria vaccine developmentA review of malaria vaccine clinical projects based on the WHO rainbow tablePaths to a malaria vaccine illuminated by parasite genomicsImmunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1T cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccinesAdenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP componentEngineering the chloroplast targeted malarial vaccine antigens in Chlamydomonas starch granulesImmune Adjuvant Effect of Molecularly-defined Toll-Like Receptor LigandsComparing the understanding of subjects receiving a candidate malaria vaccine in the United States and MaliSafety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemicTLR-based immune adjuvants.Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.Antigenicity and immunogenicity of Plasmodium vivax merozoite surface protein-3.Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.Blood stage vaccines for Plasmodium falciparum: current status and the way forward.Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36.Small molecule targeting malaria merozoite surface protein-1 (MSP-1) prevents host invasion of divergent plasmodial species.The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirusBlood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodiesCyclopropyl carboxamides, a chemically novel class of antimalarial agents identified in a phenotypic screen.Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.Recent advances in recombinant protein-based malaria vaccines.Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infectionA Novel Malaria Pf/Pv Ab Rapid Diagnostic Test Using a Differential Diagnostic Marker Identified by Network Biology.Progress and prospects for blood-stage malaria vaccinesA monoclonal antibody against the human SUMO-1 protein obtained by immunization with recombinant protein and CpG-DNA-liposome complex.A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodiesSafety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-Immune Adults: A Phase 1, Double-Blinded Placebo Controlled Dosage Escalation Study.TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants.Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.Recent progress concerning CpG DNA and its use as a vaccine adjuvant.The path of malaria vaccine development: challenges and perspectives.Rice-produced MSP142 of Plasmodium falciparum elicits antibodies that inhibit parasite growth in vitro.Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research.Evaluation of a Plasmodium-specific carrier protein to enhance production of recombinant Pfs25, a leading transmission-blocking vaccine candidate.Profiling invasive Plasmodium falciparum merozoites using an integrated omics approach.Strain-transcending neutralization of malaria parasite by antibodies against Plasmodium falciparum enolasemalaria: current research perspectives
P2860
Q21032463-10207662-64D2-44E6-9D6E-66442E12457DQ21034112-9BAD1BCC-ADB5-48A5-ADE9-D75618270D30Q26853267-991DE3A3-5C47-488B-AED7-741AD0D5C34DQ28484081-BDD456C7-5400-4A05-98F8-5B35869CB96EQ28740432-7C3FFE32-4C2F-4FB3-A8C1-D9E7617C95B0Q28744136-C384911A-6EE2-44EA-AE58-16C5572C72DDQ28744199-B875B752-0AA1-42A3-AE49-2E1AC11FB6EBQ28972540-02E8DA41-5A82-4C16-B9C3-6F982E9312A3Q34160143-4CA5B1C3-5EE4-48FD-B636-3076A7B7A502Q34189972-3C000DF1-BADB-42F6-B2FC-047888B9245FQ34400322-0BD7E6CE-EE8C-42E4-8318-F78528D5C4CAQ34441098-CFD9499F-CEB9-42E9-90C0-C95BD3EC6425Q34606478-C9FA57D9-636A-4D58-A933-A7047AC2B71EQ34613585-EA58CB67-AB98-4EF4-B3C5-038F5398D2C4Q34663978-706283B7-8420-426D-81F3-D85472260D65Q34749432-720F74AE-CC7C-4CDA-A648-3F4544B96B5AQ35102544-ACA83C78-7E2C-4D77-A0EA-FED6D6EB1EE8Q35177864-A8C35151-25F6-415E-AE5A-376B1E7B5C7BQ35456892-7F546D93-D614-4E5A-BB50-FA19781A8300Q35598598-04F8062C-6507-4107-BC9A-21330A7E7F3CQ35623459-A4C0A0D2-59AA-4104-B8CA-832F7CA9108AQ36394182-180181AF-CEE0-479D-8844-34FF757F7C2FQ36639261-E5EFA6BF-B395-4B38-966E-A100D84079D2Q36903515-85DA364A-61B2-4A48-87C0-1A22C80368F0Q37012137-84646D83-9A8D-47D0-BBFB-AF1AC674F845Q37025030-70C2A390-51CC-464D-99D5-088EB38E41BCQ37233554-72D567CE-2E61-47D9-A6FD-4DE1E669911DQ37264673-3273B0C5-A8B3-4CF2-A1F2-AEC5D784651EQ37265801-2B4E234E-FBCE-4C82-B6CB-20284BD052D3Q37384724-F8409AA2-C05A-4DC4-9A80-8B90AC418EDEQ37981769-24ADE3D6-A783-45FF-86B4-299F11A08AA6Q38096490-8280CCA2-C8F4-480B-9676-522DA6B02F41Q38168903-0099A004-4E38-4CCB-9F2D-8EAB66ED36E1Q38196455-8C5662CC-3285-4578-A247-ED1B59EF37D8Q38942086-BEE74B84-39D4-4EC2-B290-D0E2B912500BQ40752357-5FB781C1-63DD-4F54-A575-3E50D12C775FQ41989340-8B54CD79-D87F-4046-B471-375ED40FC4ABQ47111142-C85C704F-6FD5-44BF-8F06-1B3F2FB48262Q56342063-2BBB1B75-7AF3-497B-8822-9DD599270099Q56344544-2B1AC526-6510-4211-B7A2-C483B0907EF7
P2860
Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase 1 trial of the Plasmodiu ...... G 7909 in malaria naïve adults
@ast
Phase 1 trial of the Plasmodiu ...... G 7909 in malaria naïve adults
@en
Phase 1 trial of the Plasmodiu ...... G 7909 in malaria naïve adults
@nl
type
label
Phase 1 trial of the Plasmodiu ...... G 7909 in malaria naïve adults
@ast
Phase 1 trial of the Plasmodiu ...... G 7909 in malaria naïve adults
@en
Phase 1 trial of the Plasmodiu ...... G 7909 in malaria naïve adults
@nl
prefLabel
Phase 1 trial of the Plasmodiu ...... G 7909 in malaria naïve adults
@ast
Phase 1 trial of the Plasmodiu ...... G 7909 in malaria naïve adults
@en
Phase 1 trial of the Plasmodiu ...... G 7909 in malaria naïve adults
@nl
P2093
P2860
P50
P921
P3181
P1433
P1476
Phase 1 trial of the Plasmodiu ...... G 7909 in malaria naïve adults
@en
P2093
Daming Zhu
Donna Shaffer
Gregory E D Mullen
Laura B Martin
P2860
P3181
P356
10.1371/JOURNAL.PONE.0008787
P407
P50
P577
2010-01-22T00:00:00Z